RUO

Oncocyte Reports First Quarter 2024 Financial Results

Retrieved on: 
星期三, 五月 15, 2024
Insurance, Security (finance), Partnership, RUO, FDA, Telephone, Marketing, Bio-Rad Laboratories, OCX, Research, Therapy, IVD

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.
  • “In the first quarter of 2024, Oncocyte made significant progress toward commercializing its innovative blood-based diagnostic tests.
  • For Oncocyte’s complete financial results for the first quarter ended March 31, 2024, see the Company’s quarterly Form 10-Q to be filed with the Securities and Exchange Commission on May 15, 2024.
  • Oncocyte will host a conference call to discuss first quarter 2024 financial results after market close on Wednesday, May 15, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
星期一, 五月 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)

Retrieved on: 
星期二, 五月 7, 2024
RUO, Good manufacturing practice, Safety, Expansion, RNA, Cell, Research, Bio-Techne, Small, Science, Patient, Gene, Society, Medicine, Messenger, Good, GMP, Vaccine

MINNEAPOLIS, May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • MINNEAPOLIS, May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.
  • We will also feature our "Immune Cell Therapy Workflow" multimedia experience, which enables attendees to explore how Bio-Techne's solutions streamline and accelerate the immune cell processing workflow.
  • The topics covered will include characterizing biodistribution and safety of cell and gene therapies, protein analytics strategies for gene therapy, and advancements in closed systems and non-viral cell engineering for immune cell therapy manufacturing.
  • "Bio-Techne's portfolio plays a critical role in the development of next-generation cell and gene therapies.

Microbix Collaborator Introduces New Lab Accreditation Program

Retrieved on: 
星期四, 四月 25, 2024
RUO, Mycoplasma genitalium, EQA, Pelvic inflammatory disease, Infection, OTCQX, Woman, Infertility, Poster, Bacteria, MDX, AMR, ECCMID, TSX, STI, Accreditation, Vertically transmitted infection, Temperature, Drug resistance, Chronic pain, Non-gonococcal urethritis, Ectopic pregnancy, IVD

The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.

Key Points: 
  • The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.
  • The pilot EQA program confirmed the performance of these QAPs across all clinical labs, instrument platforms, and assays.
  • These Mgen QAPs are now available from Microbix as part of its PROCEEDx®FLOQ® (RUO) or REDx™FLOQ® (IVD) catalogue of products.
  • Purchase enquiries for these or other Microbix QAPs can be e-mailed to [email protected] .

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Retrieved on: 
星期五, 四月 26, 2024
Biotechnology, Health, Genetics, Science, Research, MALDI, RUO, Yeast, Infection, Gastroenteritis, Piperacillin/tazobactam, HAI, Hospital, Antimalarial medication, Certification, Mycobacterium tuberculosis, Fungal infection, Bacteria, ESCMID, Daptomycin, Patient, Microbiology, Acquisition, Multimedia, Gram-negative bacteria, Diagnosis, Colistin, IVDR, TB, IVD, Sepsis, MBT, Sirius, Vaccine

At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays.

Key Points: 
  • At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays.
  • Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions.
  • Bruker offers additional clinical workflows for rapid functional antibiotic resistance testing, like the MBT STAR®-Carba IVD assay for the detection of carbapenemase activity.
  • Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, commented: “Bruker is committed to innovation in routine microbiology and infectious disease testing.

NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development

Retrieved on: 
星期二, 四月 16, 2024
Health, Health Technology, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, RUO, CBUS, CBU, Investment, NMDP, Match, Collection, Research, KIR, Drug Master File, Cryopreservation, Patient, GMP, DMF, CD16, Organization, Medical device

NMDP BioTherapies ℠, formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.

Key Points: 
  • NMDP BioTherapies ℠, formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.
  • “We have leveraged over three decades of experience in managing cellular product collections, working closely with cell and gene therapy developers to deliver an advanced allogeneic suite of compliant products,” said Tom Hochuli, President of NMDP BioTherapies.
  • “These investments in our cellular starting material offerings are a testament to our commitment to advancing the cell and gene therapy industry.
  • Recognizing the diverse stages of cell therapy development, NMDP BioTherapies has broadened its RUO leukopak capabilities.

Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only

Retrieved on: 
星期一, 四月 15, 2024
Health, Medical Devices, Infectious Diseases, Genetics, Research, Science, Biotechnology, RUO, Chlamydia trachomatis, Neisseria gonorrhoeae, Laboratory, Trichomonas vaginalis, Collection, STI, DNA, SNP, Mycoplasma genitalium, Vaccine

Applied BioCode Inc., a pioneer in molecular diagnostics, proudly announces the launch of its latest innovation, the BioCode® STI + Resistance Panel (RUO).

Key Points: 
  • Applied BioCode Inc., a pioneer in molecular diagnostics, proudly announces the launch of its latest innovation, the BioCode® STI + Resistance Panel (RUO).
  • The panel is exclusively intended for research purposes and is not intended for diagnostic procedures.
  • Engineered with precision for seamless integration with the BioCode® MDx-3000 automated system, it delivers timely test results approximately 4 hours post-DNA extraction.
  • “We are thrilled to announce the release of the STI + Resistance Panel for research use under our new product strategy.

Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing

Retrieved on: 
星期五, 四月 12, 2024
CDX, Nucleic acid thermodynamics, Tissue, NGS, DNA, RUO, Laboratory, Urine, BDD, Cancer, Liquid biopsy, Deletion, Blood, FDA, Food

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.

Key Points: 
  • HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.
  • This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.
  • This newly introduced PredicineCARE™ NGS kit integrates a comprehensive, state-of-the-art NGS assay capable of detecting point mutations, indels, fusions, amplifications, and deletions in key cancer-associated genes.
  • “Predicine’s centralized global lab network coupled with the decentralized kitted offering provides a standardized approach to support clinical trials, CDx development and patient testing on a global scale.”

Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research

Retrieved on: 
星期五, 三月 15, 2024
Research, Medical Devices, Medical Supplies, Baby, Maternity, Genetics, Health Technology, Health, Consumer, Science, Quality control, SVP, Workflow, FACMG, NGS, Element, Database, Gene, Collection, RUO, Doctor of Philosophy

Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.

Key Points: 
  • Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.
  • “This new workflow from Revvity seeks to elevate the customer experience by leveraging a rich variant database for newborn sequencing research and providing critical components necessary to be able to go from sample to result,” said Madhuri Hegde, PhD, FACMG, SVP and chief scientific officer, Revvity.
  • “We are accelerating the democratization of genomic sequencing by addressing the typical challenges faced by labs.”
    The research-use only (RUO) offering from Revvity culminates in analysis and report, covering essential steps in the sequencing process.
  • The solution enables identification of variants in more than 350 genes, complemented by a large database of carefully pre-curated variants.

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
星期二, 三月 12, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Biometrics, Other Health, Health, Other Science, Science, Neurodegenerative disease, Fujirebio, DirectX, Partnership, Patient, Biomarker, RUO, IVD, Beckman Coulter, Apolipoprotein E, Therapy, Physician, AFL, Amyloid, Medical imaging

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer’s disease therapeutics.
  • These new assays are being developed for use on the recently introduced Beckman Coulter DxI 9000 Immunoassay Analyzer.
  • Kevin O’Reilly, President, Beckman Coulter Diagnostics, commented, “We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream.”
    “Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”